This company has been acquired
Blueprint Medicines Beheer
Beheer criteriumcontroles 2/4
De CEO Blueprint Medicines is Kate Haviland, benoemd in Apr2022, heeft een ambtstermijn van 3.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 13.48M, bestaande uit 6.1% salaris en 93.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.11% van de aandelen van het bedrijf, ter waarde $ 9.14M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5 jaar en 10.2 jaar.
Belangrijke informatie
Kate Haviland
Algemeen directeur
US$13.5m
Totale compensatie
| Percentage CEO-salaris | 6.09% |
| Dienstverband CEO | 3.3yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 5yrs |
| Gemiddelde ambtstermijn bestuur | 10.2yrs |
Recente managementupdates
Recent updates
Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade
Summary Sanofi's deal to acquire Blueprint was announced on June 2nd ,for an initial amount of $9.1bn, or $129 per share. Sanoi will acquire Blueprint's approved drug for mastocytosis Aykavit, which earned $150m last quarter, and could reach $2bn in revenues by 2030. There are contingent value rights that may pay up to $6 per share based on a pipeline drug, BLU-808, achieving certain milestones. Sanofi had the money and the desire to do the deal, and the price paid will likely satisfy Bluerprint shareholders - up >600% since IPO. This is, therefore, a good deal for Sanofi, and Blueprint, and could kick off a bull run on stock, as Aykavit will be immediately revenue accretive. Read the full article on Seeking Alpha
Expanding Patient Reach And Pipeline Development Will Unlock Potential
Strong AYVAKIT demand, expanded market reach, and improved therapy duration fuel revenue growth and enhance operating margin stability.Blueprint Medicines: Strong Business, Ambitious Targets, Expensive Stock
Summary Blueprint Medicines' primary revenue driver is Ayvakit, approved for various forms of Systemic Mastocytosis (SM) and showing strong growth, with 2024 revenues at $479m. The company projects Ayvakit to reach $2 billion in annual revenues by 2030, with significant growth potential as only 10% of the diagnosed SM market is penetrated. Blueprint is developing next-generation drugs like elenestinib and BLU-808, which could further enhance its SM franchise and diversify its revenue streams. Despite impressive growth and a strong cash position, I recommend a "hold" due to the stock's high valuation and the need for pipeline drugs to be further derisked. Read the full article on Seeking AlphaBlueprint Medicines: Growth For The Long Term Still Mostly Priced In
Summary Despite solid earnings beats, Blueprint Medicines is trading down ~16% since my last article. AYVAKIT/AYVAKYT revenues have doubled for four consecutive years, with 2024 guidance pegging net product revenue at $435-$450 million, a ~117% increase from 2023. CEO Haviland highlights AYVAKIT's multibillion-dollar potential, driven by its unique value proposition and strong adoption among physicians, patients, and payers. Blueprint's revised revenue guidance is based on strong first-half 2024 performance and growing experience with factors driving its business, particularly in systemic mastocytosis treatment. Read the full article on Seeking AlphaBlueprint Medicines: Overdue For A Breather
Summary Today, we take a look at Blueprint Medicines Corporation, a company focused on developing precision therapies for cancers and blood disorders. Blueprint's Q1 results were spectacular, and the company has a solid balance sheet, but the stock is up more than 150% from its lows in late October. Can the shares rally further, or are they overdue for a breather? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaBlueprint Medicines: Rampant Growth Mostly Priced In
Summary Blueprint Medicines generates growing revenues from its FDA-approved product AYVAKIT/AYVAKYT. AYVAKIT has been approved for multiple indications, including gastrointestinal stromal tumor and systemic mastocytosis. Blueprint reported strong Q1 2024 earnings, achieving $92.5 million in AYVAKIT net product revenues and raising guidance for full-year revenues. Read the full article on Seeking AlphaBlueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Summary Blueprint Medicines' Ayvakit shows strong performance in the ISM market, with revenue projections increased to $2 billion. Q4 '23 earnings highlight significant growth, with Ayvakit driving revenues up and a strong cash position despite a high burn rate. Market sentiment is robust, supported by strong analyst projections, institutional interest, and stock momentum. I am upgrading my rating to a "strong buy," considering Ayvakit's market potential, financial health, and Blueprint's strategic positioning despite biotech investment risks. Read the full article on Seeking AlphaAnalyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$156m |
| Dec 31 2024 | US$13m | US$821k | -US$67m |
| Sep 30 2024 | n/a | n/a | -US$128m |
| Jun 30 2024 | n/a | n/a | -US$205m |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$6m | US$782k | -US$507m |
| Sep 30 2023 | n/a | n/a | -US$555m |
| Jun 30 2023 | n/a | n/a | -US$554m |
| Mar 31 2023 | n/a | n/a | -US$581m |
| Dec 31 2022 | US$6m | US$701k | -US$558m |
| Sep 30 2022 | n/a | n/a | -US$718m |
| Jun 30 2022 | n/a | n/a | -US$702m |
| Mar 31 2022 | n/a | n/a | -US$650m |
| Dec 31 2021 | US$4m | US$501k | -US$644m |
| Sep 30 2021 | n/a | n/a | -US$411m |
| Jun 30 2021 | n/a | n/a | US$340m |
| Mar 31 2021 | n/a | n/a | US$325m |
| Dec 31 2020 | US$2m | US$461k | US$314m |
| Sep 30 2020 | n/a | n/a | US$333m |
| Jun 30 2020 | n/a | n/a | -US$395m |
| Mar 31 2020 | n/a | n/a | -US$371m |
| Dec 31 2019 | US$3m | US$432k | -US$348m |
| Sep 30 2019 | n/a | n/a | -US$362m |
| Jun 30 2019 | n/a | n/a | -US$340m |
| Mar 31 2019 | n/a | n/a | -US$267m |
| Dec 31 2018 | US$3m | US$393k | -US$237m |
Compensatie versus markt: De totale vergoeding ($USD 13.48M ) Kate } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.29M ).
Compensatie versus inkomsten: De vergoeding van Kate is gestegen terwijl het bedrijf verliesgevend is.
CEO
Kate Haviland (49 yo)
Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 3.3yrs | US$13.48m | 0.11% $ 9.1m | |
| Co-Founder & Director | no data | US$549.69k | 0.11% $ 9.6m | |
| Chief Financial Officer | 9.4yrs | US$4.19m | 0.067% $ 5.6m | |
| Chief Operating Officer | 3.3yrs | US$6.54m | 0.032% $ 2.7m | |
| Chief Scientific Officer | 4.2yrs | US$5.13m | 0.082% $ 6.9m | |
| President of Research & Development | 4.8yrs | US$5.50m | 0.049% $ 4.1m | |
| Senior Vice President of Finance and Principal Accounting Officer | no data | geen gegevens | 0.026% $ 2.2m | |
| Senior Director & Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive VP | 8.8yrs | US$2.34m | 0.057% $ 4.8m | |
| Chief People Officer | 5.4yrs | geen gegevens | 0.035% $ 3.0m | |
| Senior Vice President of Corporate Affairs | no data | geen gegevens | geen gegevens | |
| Chief Medical Officer | 5.2yrs | geen gegevens | 0.047% $ 3.9m |
Ervaren management: Het managementteam van BPMC is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 3.3yrs | US$13.48m | 0.11% $ 9.1m | |
| Co-Founder & Director | 14.3yrs | US$549.69k | 0.11% $ 9.6m | |
| Chair of Scientific Advisory Board | 13.2yrs | US$333.38k | geen gegevens | |
| Lead Independent Director | 9.3yrs | US$606.19k | 0.020% $ 1.7m | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board & Independent Director | 14.3yrs | US$569.69k | 0.086% $ 7.2m | |
| Independent Director | 9.4yrs | US$572.59k | 0.0035% $ 289.6k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 3.6yrs | US$574.69k | 0.017% $ 1.4m | |
| Chairman of the Board of Director | 11yrs | US$586.19k | 0.22% $ 18.7m |
Ervaren bestuur: De raad van bestuur van BPMC zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.2 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2025/07/17 15:38 |
| Aandelenkoers aan het einde van de dag | 2025/07/17 00:00 |
| Inkomsten | 2025/03/31 |
| Jaarlijkse inkomsten | 2024/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Blueprint Medicines Corporation wordt gevolgd door 10 analisten. 19 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| George Farmer | BMO Capital Markets Equity Research |
| Dane Leone | BTIG |
| Arlinda Lee | Canaccord Genuity |